Follicular Lymphoma: Interactions With Surrounding Cells to Identify Therapeutic Targets
Characterizing gene expression profiles of FL cells from intrafollicular and extrafollicular regions may help to identify future therapeutic targets.
Non-Hodgkin Lymphoma
Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
2021 Update on Diagnosis, Risk Stratification, and Management of Cutaneous B-Cell Lymphomas
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Managing Skin Flare Reactions in Patients Receiving Mogamulizumab for Cutaneous T-cell Lymphoma
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Lipid Microenvironment With B-Cell Lymphoma and Natural Killer Cell Function
Lipid changes in the B-cell lymphoma microenvironment may influence natural killer cell metabolism and function.
Survival Outcomes and HIV Status Among Patients With Plasmablastic Lymphoma
Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
Immunohistochemistry as a Surrogate for TP53 Sequencing in Mantle Cell Lymphoma
Identifying TP53 missense mutations through routine analysis is needed for patients with mantle cell lymphoma.
Risk-Stratified Treatments May Offer Cures in Relapsed Pediatric Anaplastic Large Cell Lymphoma
Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.
-
Loading...
-
Loading...
Next post in Lymphoma
